A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications

Description

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Trial Eligibility

Inclusion Criteria: * History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to \<60 mL/min/1.73m\^2 * Mean seated office SBP ≥140 mmHg and ≤170 mmHg * 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM * Must be on stable therapy with 2 to 4 classes of antihypertensive medications Exclusion Criteria: * Secondary hypertension * Orthostatic hypotension * Proteinuria \>3 g/day * Serum potassium \>4.8 milliequivalents per liter (mEq/L)

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.